[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[S. Res. 474 Agreed to Senate (ATS)]

<DOC>






118th CONGRESS
  1st Session
S. RES. 474

         Designating November 2023 as American Diabetes Month.


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                           November 27, 2023

  Mrs. Shaheen (for herself and Ms. Collins) submitted the following 
             resolution; which was considered and agreed to

_______________________________________________________________________

                               RESOLUTION


 
         Designating November 2023 as American Diabetes Month.

Whereas, according to the Centers for Disease Control and Prevention (referred 
        to in this preamble as the ``CDC'')--

    (1) an estimated 37,300,000 individuals in the United States have 
diabetes; and

    (2) an estimated 96,000,000 individuals in the United States who are 18 
years of age or older have prediabetes;

Whereas diabetes is a serious chronic condition that affects individuals of 
        every age, race, ethnicity, and income level;
Whereas the CDC reports that--

    (1) Hispanic, Black, Asian, American Indian, and Alaska Native adults 
in the United States are disproportionately affected by diabetes and 
develop the disease at much higher rates than the general population of the 
United States; and

    (2) an estimated 23 percent of individuals with diabetes in the United 
States have not yet been diagnosed with the disease;

Whereas, in the United States, an estimated 11.3 percent of the population, 
        including 29.2 percent of individuals who are 65 years of age or older, 
        have diabetes;
Whereas, of the approximately 16,200,000 veterans in the United States, 1 in 4 
        are receiving care for diabetes from the Department of Veterans Affairs;
Whereas the risk of developing type 2 diabetes at some point in life is 40 
        percent for adults in the United States;
Whereas, according to the American Diabetes Association--

    (1) in 2022, the estimated direct and indirect medical costs in the 
United States for cases of diagnosed diabetes was $412,900,000,000; and

    (2) as insulin prices rise, 1 in 4 individuals using insulin report 
reducing use due to insulin cost;

Whereas the American Diabetes Association reports that, in 2017, care for 
        individuals with diagnosed diabetes accounted for 1 in 4 health care 
        dollars in the United States;
Whereas the cost of health care is estimated to be 2.6 times higher for 
        individuals in the United States with diabetes than those without 
        diabetes;
Whereas, as of November 2023, a cure for diabetes does not exist;
Whereas there are successful means to reduce the incidence, and delay the onset, 
        of type 2 diabetes;
Whereas, with proper management and treatment, individuals with diabetes live 
        healthy and productive lives; and
Whereas individuals in the United States celebrate American Diabetes Month in 
        November: Now, therefore, be it
    Resolved, That the Senate designates November 2023 as American 
Diabetes Month, supporting the goals and ideals of American Diabetes 
Month, including--
            (1) encouraging individuals in the United States to fight 
        diabetes through public awareness of prevention and treatment 
        options; and
            (2) enhancing diabetes education;
            (3) recognizing the importance of awareness and early 
        detection, including awareness of symptoms and risk factors 
        such as--
                    (A) being--
                            (i) older than 45 years of age; or
                            (ii) overweight; and
                    (B) having--
                            (i) a particular racial and ethnic 
                        background;
                            (ii) a low level of physical activity;
                            (iii) high blood pressure;
                            (iv) a family history of diabetes; or
                            (v) a history of diabetes during pregnancy;
            (4) supporting a decrease in the prevalence of type 1, type 
        2, and gestational diabetes in the United States through 
        research, treatment, and prevention; and
            (5) recognizing the importance of addressing barriers to 
        health care that--
                    (A) leave many communities at a heightened risk for 
                diabetes; and
                    (B) limit access to health care resources that are 
                needed to effectively prevent the onset, and to manage 
                the condition, of diabetes.
                                 <all>